Literature DB >> 20008657

Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease.

Roy N Alcalay1, Helen Mejia-Santana, Ming Xin Tang, Llency Rosado, Miguel Verbitsky, Sergey Kisselev, Barbara M Ross, Elan D Louis, Cynthia L Comella, Amy Colcher, Danna Jennings, Martha A Nance, Susan Bressman, William K Scott, Caroline Tanner, Susan F Mickel, Howard F Andrews, Cheryl H Waters, Stanley Fahn, Lucien J Cote, Steven J Frucht, Blair Ford, Michael Rezak, Kevin Novak, Joseph H Friedman, Ronald Pfeiffer, Laura Marsh, Bradley Hiner, Andrew Siderowf, Elise Caccappolo, Ruth Ottman, Lorraine N Clark, Karen S Marder.   

Abstract

OBJECTIVE: To determine the motor phenotype of LRRK2 G2019S mutation carriers. LRRK2 mutation carriers were previously reported to manifest the tremor dominant motor phenotype, which has been associated with slower motor progression and less cognitive impairment compared with the postural instability and gait difficulty (PIGD) phenotype.
DESIGN: Cross-sectional observational study.
SETTING: Thirteen movement disorders centers. PARTICIPANTS: Nine hundred twenty-five early-onset Parkinson disease cases defined as age at onset younger than 51 years. MAIN OUTCOME MEASURES: LRRK2 mutation status and Parkinson disease motor phenotype: tremor dominant or PIGD. Demographic information, family history of Parkinson disease, and the Unified Parkinson's Disease Rating Scale score were collected on all participants. DNA samples were genotyped for LRRK2 mutations (G2019S, I2020T, R1441C, and Y1699C). Logistic regression was used to examine associations of G2019S mutation status with motor phenotype adjusting for disease duration, Ashkenazi Jewish ancestry, levodopa dose, and family history of Parkinson disease.
RESULTS: Thirty-four cases (3.7%) (14 previously reported) were G2019S carriers. No other mutations were found. Carriers were more likely to be Ashkenazi Jewish (55.9% vs 11.9%; P < .001) but did not significantly differ in any other demographic or disease characteristics. Carriers had a lower tremor score (P = .03) and were more likely to have a PIGD phenotype (92.3% vs 58.9%; P = .003). The association of the G2019S mutation with PIGD phenotype remained after controlling for disease duration and Ashkenazi Jewish ancestry (odds ratio, 17.7; P < .001).
CONCLUSION: Early-onset Parkinson disease G2019S LRRK2 carriers are more likely to manifest the PIGD phenotype, which may have implications for disease course.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008657      PMCID: PMC2837584          DOI: 10.1001/archneurol.2009.267

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  26 in total

Review 1.  Prognostic factors for the progression of Parkinson's disease: a systematic review.

Authors:  Bart Post; Maruschka P Merkus; Rob J de Haan; Johannes D Speelman
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

2.  Genotypic and phenotypic characteristics of Dutch patients with early onset Parkinson's disease.

Authors:  Maria G Macedo; Dagmar Verbaan; Yue Fang; Stephanie M van Rooden; Martine Visser; Burcu Anar; Antonella Uras; Justus L Groen; Patrizia Rizzu; Jacobus J van Hilten; Peter Heutink
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

Review 3.  A genetic profile of contemporary Jewish populations.

Authors:  H Ostrer
Journal:  Nat Rev Genet       Date:  2001-11       Impact factor: 53.242

4.  G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.

Authors:  Carles Gaig; María José Martí; Mario Ezquerra; Maria Jesús Rey; Adriana Cardozo; Eduardo Tolosa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-08       Impact factor: 10.154

5.  Frequency of LRRK2 mutations in early- and late-onset Parkinson disease.

Authors:  L N Clark; Y Wang; E Karlins; L Saito; H Mejia-Santana; J Harris; E D Louis; L J Cote; H Andrews; S Fahn; C Waters; B Ford; S Frucht; R Ottman; K Marder
Journal:  Neurology       Date:  2006-10-18       Impact factor: 9.910

6.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Authors:  Daniel G Healy; Mario Falchi; Sean S O'Sullivan; Vincenzo Bonifati; Alexandra Durr; Susan Bressman; Alexis Brice; Jan Aasly; Cyrus P Zabetian; Stefano Goldwurm; Joaquim J Ferreira; Eduardo Tolosa; Denise M Kay; Christine Klein; David R Williams; Connie Marras; Anthony E Lang; Zbigniew K Wszolek; Jose Berciano; Anthony H V Schapira; Timothy Lynch; Kailash P Bhatia; Thomas Gasser; Andrew J Lees; Nicholas W Wood
Journal:  Lancet Neurol       Date:  2008-06-06       Impact factor: 44.182

7.  Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study.

Authors:  David J Burn; Elise N Rowan; Thais Minett; Jonathon Sanders; Pat Myint; Jonathon Richardson; Alan Thomas; Jane Newby; Jenny Reid; John T O'Brien; Ian G McKeith
Journal:  Mov Disord       Date:  2003-08       Impact factor: 10.338

8.  Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screening.

Authors:  Jordi Clarimón; Javier Pagonabarraga; Coro Paisán-Ruíz; Antonia Campolongo; Berta Pascual-Sedano; José-Félix Martí-Massó; Andrew B Singleton; Jaime Kulisevsky
Journal:  Mov Disord       Date:  2008-03-15       Impact factor: 10.338

9.  Cognitive impairment in Parkinson's disease.

Authors:  D Verbaan; J Marinus; M Visser; S M van Rooden; A M Stiggelbout; H A M Middelkoop; J J van Hilten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-18       Impact factor: 10.154

Review 10.  Clinical diagnostic criteria for dementia associated with Parkinson's disease.

Authors:  Murat Emre; Dag Aarsland; Richard Brown; David J Burn; Charles Duyckaerts; Yoshikino Mizuno; Gerald Anthony Broe; Jeffrey Cummings; Dennis W Dickson; Serge Gauthier; Jennifer Goldman; Christopher Goetz; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Ian McKeith; Warren Olanow; Werner Poewe; Niall Quinn; Christina Sampaio; Eduardo Tolosa; Bruno Dubois
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

View more
  21 in total

1.  Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.

Authors:  Roy N Alcalay; Helen Mejia-Santana; Anat Mirelman; Rachel Saunders-Pullman; Deborah Raymond; Christina Palmese; Elise Caccappolo; Laurie Ozelius; Avi Orr-Urtreger; Lorraine Clark; Nir Giladi; Susan Bressman; Karen Marder
Journal:  Parkinsonism Relat Disord       Date:  2014-11-20       Impact factor: 4.891

2.  Genetic markers of Restless Legs Syndrome in Parkinson disease.

Authors:  Ziv Gan-Or; Roy N Alcalay; Anat Bar-Shira; Claire S Leblond; Ronald B Postuma; Shay Ben-Shachar; Cheryl Waters; Amelie Johnson; Oren Levy; Anat Mirelman; Mali Gana-Weisz; Nicolas Dupré; Jacques Montplaisir; Nir Giladi; Stanley Fahn; Lan Xiong; Patrick A Dion; Avi Orr-Urtreger; Guy A Rouleau
Journal:  Parkinsonism Relat Disord       Date:  2015-03-17       Impact factor: 4.891

3.  Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.

Authors:  Vicki Shanker; Mark Groves; Gary Heiman; Christina Palmese; Rachel Saunders-Pullman; Laurie Ozelius; Deborah Raymond; Susan Bressman
Journal:  Mov Disord       Date:  2011-05-24       Impact factor: 10.338

4.  Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study.

Authors:  Roy N Alcalay; Elise Caccappolo; Helen Mejia-Santana; Ming Xin Tang; Llency Rosado; Barbara M Ross; Miguel Verbitsky; Sergey Kisselev; Elan D Louis; Cynthia Comella; Amy Colcher; Danna Jennings; Martha A Nance; Susan B Bressman; William K Scott; Caroline Tanner; Susan Mickel; Howard Andrews; Cheryl Waters; Stanley Fahn; Lucien Cote; Steven Frucht; Blair Ford; Michael Rezak; Kevin Novak; Joseph H Friedman; Ronald Pfeiffer; Laura Marsh; Bradley Hiner; Andrew Siderowf; Ruth Ottman; Karen Marder; Lorraine N Clark
Journal:  Arch Neurol       Date:  2010-09

5.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

6.  Sexual dysfunction is associated with postural instability gait difficulty subtype of Parkinson's disease.

Authors:  Xiao Deng; Bin Xiao; Hui-Hua Li; Yew-Long Lo; Lai-Mun Chew; Kumar M Prakash; Eng-King Tan
Journal:  J Neurol       Date:  2015-07-26       Impact factor: 4.849

7.  Association of Parkinson disease risk loci with mild parkinsonian signs in older persons.

Authors:  Joshua M Shulman; Lei Yu; Aron S Buchman; Denis A Evans; Julie A Schneider; David A Bennett; Philip L De Jager
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

8.  Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.

Authors:  Roy N Alcalay; Anat Mirelman; Rachel Saunders-Pullman; Ming-X Tang; Helen Mejia Santana; Deborah Raymond; Ernest Roos; Martha Orbe-Reilly; Tanya Gurevich; Anat Bar Shira; Mali Gana Weisz; Kira Yasinovsky; Maayan Zalis; Avner Thaler; Andres Deik; Matthew James Barrett; Jose Cabassa; Mark Groves; Ann L Hunt; Naomi Lubarr; Marta San Luciano; Joan Miravite; Christina Palmese; Rivka Sachdev; Harini Sarva; Lawrence Severt; Vicki Shanker; Matthew Carrington Swan; Jeannie Soto-Valencia; Brooke Johannes; Robert Ortega; Stanley Fahn; Lucien Cote; Cheryl Waters; Pietro Mazzoni; Blair Ford; Elan Louis; Oren Levy; Llency Rosado; Diana Ruiz; Tsvyatko Dorovski; Michael Pauciulo; William Nichols; Avi Orr-Urtreger; Laurie Ozelius; Lorraine Clark; Nir Giladi; Susan Bressman; Karen S Marder
Journal:  Mov Disord       Date:  2013-10-15       Impact factor: 10.338

9.  Genome-Wide Association Study Meta-Analysis for Parkinson Disease Motor Subtypes.

Authors:  Isabel Alfradique-Dunham; Rami Al-Ouran; Rainer von Coelln; Cornelis Blauwendraat; Emily Hill; Lan Luo; Amanda Stillwell; Emily Young; Anita Kaw; Manuela Tan; Calwing Liao; Dena Hernandez; Lasse Pihlstrom; Donald Grosset; Lisa M Shulman; Zhandong Liu; Guy A Rouleau; Mike Nalls; Andrew B Singleton; Huw Morris; Joseph Jankovic; Joshua M Shulman
Journal:  Neurol Genet       Date:  2021-01-28

10.  Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants.

Authors:  Roy N Alcalay; Jan Aasly; Daniela Berg; Susan Bressman; Alexis Brice; Kathrin Brockmann; Piu Chan; Lorraine Clark; Florence Cormier; Jean-Christophe Corvol; Alexandra Durr; Maurizio Facheris; Matthew Farrer; Tatiana M Foroud; Thomas Gasser; Nir Giladi; Cheryl Halter; Anthony Lang; J William Langston; Connie Marras; Jose-Felix Marti-Masso; Javier Ruiz Martinez; Helen Mejia-Santana; Anat Mirelman; Claustre Pont-Sunyer; Avi Orr-Urtreger; Deborah Raymond; Rachel Saunders-Pullman; Birgitt Schüle; Caroline Tanner; Eduardo Tolosa; Alison Urkowitz; Dolores Vilas; Adina Wise; Karen Marder
Journal:  Genet Med       Date:  2014-08       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.